Currently, BC characterization includes the recently mentioned immunohistochemical markers (ER, RP, and HER2), proliferation marker proteins such as Ki67, genomic markers (BRCA1, BRCA2, PIK3CA), immunomarkers such as PD-L1, among others [19,20]. This evidence concerns the gene ERBB2 and breast cancer.